Astellas Pharma Net Income 2012-2019 | ALPMY

Astellas Pharma annual/quarterly net income history and growth rate from 2012 to 2019. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Astellas Pharma net income for the quarter ending December 31, 2019 was $M, a 100% decline year-over-year.
  • Astellas Pharma net income for the twelve months ending December 31, 2019 was $1.417B, a 23.77% decline year-over-year.
  • Astellas Pharma annual net income for 2020 was $1.798B, a 10.2% decline from 2019.
  • Astellas Pharma annual net income for 2019 was $2.002B, a 28.83% increase from 2018.
  • Astellas Pharma annual net income for 2018 was $1.554B, a 20.43% decline from 2017.
Astellas Pharma Annual Net Income
(Millions of US $)
2020 $1,798
2019 $2,002
2018 $1,554
2017 $1,953
2016 $1,608
2015 $1,236
2014 $882
2013 $881
2012 $954
2011 $836
2010 $1,319
2009 $1,761
2008 $1,714
2007 $1,091
2006 $942
Astellas Pharma Quarterly Net Income
(Millions of US $)
2019-12-31
2019-06-30 $533
2018-06-30 $502
2017-06-30 $382
2016-09-30 $475
2016-06-30 $620
2016-03-31 $259
2015-12-31 $505
2015-09-30 $478
2015-06-30 $366
2015-03-31 $163
2014-12-31 $394
2014-09-30 $327
2014-06-30 $351
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $223
2013-03-31
2012-12-31
2012-09-30
2012-06-30 $444
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $30.217B $11.967B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.157B 36.98
Takeda Pharmaceutical (TAK) Japan $55.614B 9.75
Eisai (ESALY) Japan $23.722B 20.56
UCB SA (UCBJF) Belgium $22.504B 0.00
Merck (MKGAF) Germany $15.186B 19.92
Grifols, S.A (GRFS) Spain $12.555B 15.61
Neurocrine Biosciences (NBIX) United States $11.686B 54.01
Catalent (CTLT) United States $11.365B 43.93
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 0.00
Ionis Pharmaceuticals (IONS) United States $8.387B 44.59
IPSEN SA ADR (IPSEY) France $6.994B 0.00
Orion OYJ (ORINY) Finland $6.766B 30.32
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.676B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.067B 9.71
United Therapeutics (UTHR) United States $5.325B 10.09
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $4.494B 490.67
Nektar Therapeutics (NKTR) United States $4.174B 0.00
Evotec AG (EVTCY) Germany $4.100B 110.63
Hypermarcas (HYPMY) Brazil $3.989B 12.13
FibroGen (FGEN) United States $3.754B 0.00
ChemoCentryx (CCXI) United States $3.597B 0.00
PTC Therapeutics (PTCT) United States $3.379B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.582B 10.61
Sage Therapeutics (SAGE) United States $2.251B 0.00
Pacira BioSciences (PCRX) United States $2.238B 45.81
Cronos Group (CRON) Canada $2.132B 61.10
Corcept Therapeutics (CORT) United States $1.959B 19.42
Xencor (XNCR) United States $1.821B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.796B 0.00
Indivior (INVVY) United States $1.764B 21.89
Akebia Therapeutics (AKBA) United States $1.680B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.621B 12.40
Zogenix (ZGNX) United States $1.609B 0.00
USANA Health Sciences (USNA) United States $1.558B 15.98
Heron Therapeutics (HRTX) United States $1.454B 0.00
Portola Pharmaceuticals (PTLA) United States $1.415B 0.00
Esperion Therapeutics (ESPR) United States $1.412B 0.00
Karyopharm Therapeutics (KPTI) United States $1.408B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.389B 14.97
Theravance Biopharma (TBPH) Cayman Islands $1.303B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.250B 0.00
Translate Bio (TBIO) United States $1.098B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.025B 45.76
Tilray (TLRY) Canada $0.875B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.866B 0.00
ImmunoGen (IMGN) United States $0.828B 0.00
Endo (ENDP) Ireland $0.806B 1.25
Trillium Therapeutics (TRIL) Canada $0.676B 0.00
Aerie Pharmaceuticals (AERI) United States $0.672B 0.00
Radius Health (RDUS) United States $0.649B 0.00
Molecular Templates (MTEM) United States $0.619B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.608B 0.00
Ardelyx (ARDX) United States $0.607B 0.00
Collegium Pharmaceutical (COLL) United States $0.596B 0.00
VAXART, INC (VXRT) United States $0.593B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.580B 0.00
Flexion Therapeutics (FLXN) United States $0.503B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.498B 12.05
Innate Pharma SA (IPHYF) France $0.476B 0.00
Siga Technologies (SIGA) United States $0.476B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.465B 18.14
MEI Pharma (MEIP) United States $0.453B 0.00
Ocular Therapeutix (OCUL) United States $0.440B 0.00
DURECT (DRRX) United States $0.440B 0.00
Harpoon Therapeutics (HARP) United States $0.437B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.430B 0.00
Organogenesis Holdings (ORGO) United States $0.398B 0.00
Calithera Biosciences (CALA) United States $0.369B 0.00
TherapeuticsMD (TXMD) United States $0.353B 0.00
OptiNose (OPTN) United States $0.326B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.300B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.298B 0.00
Lannett Co Inc (LCI) United States $0.285B 6.26
Concert Pharmaceuticals (CNCE) United States $0.285B 0.00
PROFOUND MEDICL (PROF) Canada $0.283B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.262B 0.00
CASI Pharmaceuticals (CASI) United States $0.249B 0.00
Redhill Biopharma (RDHL) Israel $0.240B 0.00
Rafael Holdings (RFL) United States $0.233B 0.00
Jounce Therapeutics (JNCE) United States $0.227B 5.43
Taiwan Liposome (TLC) Taiwan $0.217B 0.00
KalVista Pharmaceuticals (KALV) United States $0.216B 0.00
IMV INC (IMV) Canada $0.178B 0.00
Nivalis Therapeutics (ALPN) United States $0.177B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 23.08
Aquestive Therapeutics (AQST) United States $0.159B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.154B 0.00
Altimmune (ALT) United States $0.154B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.123B 0.00
Champions Oncology (CSBR) United States $0.114B 0.00
Recro Pharma (REPH) United States $0.111B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.110B 0.00
Otonomy (OTIC) United States $0.105B 0.00
Xeris Pharmaceuticals (XERS) United States $0.103B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.103B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.102B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.101B 0.00
Onconova Therapeutics (ONTX) United States $0.099B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.095B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.095B 0.00
MediWound (MDWD) Israel $0.092B 0.00
Sundial Growers (SNDL) Canada $0.086B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.086B 0.00
CTI BioPharma (CTIC) United States $0.085B 0.00
Biomerica (BMRA) United States $0.081B 0.00
Hemispherx BioPharma (AIM) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.073B 0.00
Heat Biologics (HTBX) United States $0.072B 0.00
Aclaris Therapeutics (ACRS) United States $0.069B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.067B 0.00
CV Sciences (CVSI) United States $0.061B 0.00
Lipocine (LPCN) United States $0.059B 0.00
RENEURON GP (RNUGF) United Kingdom $0.057B 0.00
Infinity Pharmaceuticals (INFI) United States $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.27
PolarityTE (PTE) United States $0.049B 0.00
Addex Therapeutics (ADXN) Switzerland $0.048B 0.00
Natural Alternatives (NAII) United States $0.048B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.043B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.042B 0.00
GTx (ONCT) United States $0.042B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.041B 0.00
Novan (NOVN) United States $0.040B 0.00
Mannatechorporated (MTEX) United States $0.040B 7.58
IsoRay (ISR) United States $0.038B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.038B 81.09
Neos Therapeutics (NEOS) United States $0.035B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.033B 0.00
AgeX Therapeutics (AGE) United States $0.033B 0.00
ElectroCore (ECOR) United States $0.030B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.029B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
India Globalization Capital (IGC) United States $0.022B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Flex Pharma (SLRX) United States $0.019B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.017B 0.00
Can-Fite Biopharma (CANF) Israel $0.017B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.015B 35.29
Shineco (TYHT) China $0.014B 0.00
China SXT Pharmaceuticals (SXTC) China $0.014B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
Vical (BBI) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.009B 0.00
Midatech Pharma (MTP) United Kingdom $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.009B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00